<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475421</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2014-066</org_study_id>
    <nct_id>NCT02475421</nct_id>
  </id_info>
  <brief_title>Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance</brief_title>
  <acronym>MCR Glucagon</acronym>
  <official_title>Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the elimination and degradation of glucagon in patients with type
      2 diabetes compared to matched healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present project we wish to identify whether the elimination and degradation of
      glucagon differ between healthy control subjects and patients with type 2 diabetes.
      Furthermore, we wish to examine whether obesity is an independent factor for altered glucagon
      metabolism. Thus, by examining glucagon elimination in obese subjects with and without type 2
      diabetes and in lean subjects with and without type 2 diabetes we will be able to describe
      the metabolic clearance rate (MCR) of glucagon in a broad spectrum of individuals with
      different levels of insulin resistance and beta cell dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic clearance rate of glucagon</measure>
    <time_frame>-30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut and pancreatic hormones</measure>
    <time_frame>-30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>-30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic metabolic rate</measure>
    <time_frame>-30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety, hunger, appetite - measured with visual analogue scales (VAS)</measure>
    <time_frame>-30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life and volume of distribution of glucagon</measure>
    <time_frame>-30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy, lean subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects with BMI &lt; 27 kg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy, obese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects with BMI &gt; 33 kg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic, lean subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetic subjects with BMI &lt; 27 kg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic, obese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetic subjects with BMI &gt; 33 kg/m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>One hour glucagon-clamp followed by one hour of blood sampling</description>
    <arm_group_label>Healthy, lean subjects</arm_group_label>
    <arm_group_label>Healthy, obese subjects</arm_group_label>
    <arm_group_label>Diabetic, lean subjects</arm_group_label>
    <arm_group_label>Diabetic, obese subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with type 2 diabetes

          -  Caucasians above 35 years of age with diet or/and metformin-treated type 2 diabetes of
             at least 3 month duration (diagnosed according to World Health Organization (WHO)
             criteria

          -  BMI either below 27 or above 33 kg/m^2

          -  Normal haemoglobin

          -  Informed consent

        Subjects with NGT

          -  Caucasians above 35 years of age

          -  BMI either below 27 or above 33 kg/m^2

          -  Normal HbA1c (according to WHO criteria)

          -  Normal haemoglobin

          -  Informed consent

        Exclusion Criteria:

        Patients with type 2 diabetes

          -  Inflammatory bowel disease

          -  Operation within the last 3 months

          -  Severe kidney disease (eGFR &lt; 60 ml/min)

          -  Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate
             aminotransferase (ASAT) &gt;2×normal values)

          -  Pregnancy and/or breastfeeding

          -  Age above 80 years

          -  Any condition that the investigators feel would interfere with trial participation

        Subjects with NGT

          -  Diabetes

          -  Prediabetes (impaired FPG or HbA1c above 42 mmol/mol)

          -  First-degree relatives with diabetes

          -  Inflammatory bowel disease

          -  Intestinal resection

          -  Severe kidney disease (eGFR &lt; 60 ml/min)

          -  Liver disease (ALA T and/or serum ASA T &gt;2×normal values)

          -  Pregnancy and/or breastfeeding

          -  Age above 80 years Any condition that the investigators feel would interfere with
             trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Asger Lund, MD</last_name>
    <email>Lund.asger@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Diabetes Research, Department of Medicine, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asger Lund, MD</last_name>
      <email>Lund.asger@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Magnus Grøndahl, Med. student</last_name>
      <phone>004529362445</phone>
      <email>Magnusgroendahl@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Asger Lund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magnus Grøndahl, Med. student</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Asger Lund</investigator_full_name>
    <investigator_title>Asger Lund, MD, PhD-student, University Hospital, Gentofte, Copenhagen</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Metabolic clearance rate of glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

